Ernexa Therapeutics Inc. Foreign Income Tax Expense (Benefit), Continuing Operations
Ernexa Therapeutics Inc. (ERNA) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $32.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2021-03-11
- Ernexa Therapeutics Inc. foreign income tax expense (benefit), continuing operations for fiscal 2020 was $32.00K.
- Ernexa Therapeutics Inc. foreign income tax expense (benefit), continuing operations for fiscal 2019 was -$4.00K, a 106.90% decline from fiscal 2018.
- Ernexa Therapeutics Inc. foreign income tax expense (benefit), continuing operations for fiscal 2018 was $58.00K.
- Ernexa Therapeutics Inc. foreign income tax expense (benefit), continuing operations for fiscal 2017 was -$15.00K.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month as first filed |
|---|---|---|
| 2020-12-31 | $32.00K 10-K · filed 2021-03-11 | |
| 2019-12-31 | -$4.00K 10-K · filed 2021-03-11 | |
| 2018-12-31 | $58.00K 10-K · filed 2020-03-19 | |
| 2017-12-31 | -$15.00K 10-K · filed 2019-03-22 | |
| 2016-12-31 | -$9.00K 10-K · filed 2018-03-09 | |
| 2015-12-31 | $18.00K 10-K · filed 2017-03-09 | |
| 2014-12-31 | -$62.00K 10-K · filed 2016-03-15 | |
| 2013-12-31 | -$16.00K 10-K · filed 2015-03-27 | |
| 2012-12-31 | -$2.00K 10-K · filed 2014-03-31 | $2.00K 10-K · filed 2013-03-29 |
| 2011-12-31 | $87.00K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |